GE Healthcare announced today that the U.S. Food and Drug Administration has granted clearance for the company’s newest model of Positron Emission Tomography/ Computed Tomography (PET/CT) scanner.
GE Healthcare announced today that the U.S. Food and Drug Administration has granted clearance for the company’s newest model of Positron Emission Tomography/ Computed Tomography (PET/CT) scanner. This new addition to GE’s Discovery family of scanners continues GE’s commitment to help enable the earlier detection and monitoring of disease with advanced molecular imaging technology, in both hardware and software.
The new system will be optimized for use in oncology, which represents more than 90% of clinical PET/CT exams. The system continues using the highest-sensitivity crystals in the industry, along with GE’s exclusive VUE Point HD, High Definition imaging to help clinicians advance towards the goal of Motion Free PET/CT imaging.
Motion generated by the patient’s respiration can blur small lesions affecting resolution and quantitative accuracy. VUE Point HD, combined with other GE-exclusive motion-management techniques help improve lesion detectability, treatment planning and quantitative accuracy, improved contrast-to-noise of moving lesions up to 60% vs static acquisition for overall better clinical confidence.
We anticipate shipping the first new scanners to customers in the fourth quarter of this year,” said Henry Hummel general manager of the PET/CT business at GE Healthcare. “The newest members of the Discovery line represent an outstanding evolution to GE PET/CT technology, from clinical to research applications.
As a market leader, GE has continued to focus on developing technologies that provide clinical excellence in PET/CT imaging, said Hummel, “We believe our newest PET/CT scanners are an important step toward further reducing the effects of motion and improving the physician’s ability to help patients through better clinical images.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
